Investor directory

Longitude Capital

Longitude Capital specializes in making venture growth investments in biotechnology and medical technology companies that seek to improve clinical outcomes, enhance quality of life and/or reduce system costs. They invest in both privately held and publicly traded life science companies through a variety of investment approaches. Since 2006, Longitude Capital has raised over $1.2 billion across three funds and demonstrated an ability to source, manage and exit attractive investments across multiple market cycles. Their venture growth strategy is rooted in building a balanced portfolio of clinical-stage and commercial-stage companies with clinically de-risked assets, favorable valuations relative to risk profile and attractive expected returns within three to five years from initial investment. Longitude Capital seeks to identify new investment opportunities by tapping into their broad network of industry relationships or through the execution of intensive thematic research into emerging therapeutic areas or industry sub-sectors. They utilize a variety of investment structures, including traditional venture capital, asset spin-outs, recapitalizations, PIPEs, open market purchases, royalties and other equity and equity-linked instruments.

Focus

Mid VentureTherapeuticsSeries BSeries AEarly VentureShow more
http://www.longitudecapital.com
https://angel.co/longitude-capital
https://crunchbase.com/organization/longitude-capital
https://linkedin.com/company/longitude-capital
https://signal.nfx.com/firms/longitude-capital
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=37260572
https://www.privateequityinternational.com/database/#/profile?id=8664

Sandip Agarwala

MD

Irvin Akinseye

Associate

Juliet Bakker

MD

Maxwell Bikoff

Principal

Patrick Enright

MD

Marc Galletti

MD

Marc-Henri Galletti

Co-Founder and MD

Gregory Grunberg

MD

Varun Gupta

VP

Carolyn Helms

CFO

David Hirsch

MD

Oren Isacoff

Principal

Maggie Jamison

Manager of Investor Relations and Marketing

Victoria Lai

VP

Michelle Li

Associate

Zander Liem

Senior Associate

Brian Liu

Principal

Sonia Parekh

Associate

Amar Patel

Associate

Hyde Patterson

Associate

Josh Richardson

MD

Josh Sherman

VP

Michael Wert

Principal

134 past transactions

MURJ

Series B in 2018
Murj is a Santa Cruz, California digital health company dedicated to helping clinicians streamline care for patients with implantable cardiac devices. Murj greets the challenge of managing the rapid growth of cardiac device data as an opportunity to improve care and deliver insight. Murj aims to liberate device clinics from paper reports and inadequate management tools, freeing clinicians to get back to the heart of the matter – their patients.

Orbus Therapeutics

Series A in 2015
They at Orbus are committed to bringing innovative products to the extremely underserved patients affected by rare diseases. They are focused and passionate about bringing a more positive outcome to patients facing life-threatening or significantly life-altering diseases. Currently, Orbus Therapeutics is working to develop and commercialize eflornithine in North America. The company was founded in 2012 and is headquartered in Palo Alto, California.

Whitehill Technologies

Series A in 2001
Whitehill develops software designed to take data and information created in the pre-Internet era and use XML (Extensible Markup Language) to allow the material to be posted on the Internet.

Sublimity Therapeutics

Venture Round in 2018
Sublimity Therapeutics (formerly Sigmoid Pharma), is a specialty pharma company with offices in Dublin, Ireland, and Solana Beach, California. Sublimity’s goal is to identify and create meaningful new therapies for unmet clinical needs in gastrointestinal and immunological diseases. Sublimity’s priority focus is on its lead product, STI-0529, for treatment of moderate to severe ulcerative colitis.

Inozyme

Series A in 2017
Inozyme is a provider of therapies for rare diseases of calcification affecting soft tissues and bone created to offer potentially disease-modifying therapies to help children who are affected with rare, but severe and debilitating disorders of metabolism. The company's enzyme replacement therapy provides the treatment of Generalized Arterial Calcification of Infancy (GACI) and Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2), enabling patients to treat diseases characterized by mineral imbalances in the body.

AqueSys

Series D in 2014
AqueSys, Inc., an ophthalmic company, focuses on innovating and commercializing implantable devices that improves the treatment of glaucoma. It offers XEN, a gel stent that creates a diffuse outflow of aqueous from the anterior chamber into the non-dissected tissue of the subconjunctival space. The company’s XEN gel stent creates a new pathway to allow the excess fluid in eyes to flow out, and lowers the eye pressure. AqueSys, Inc. was incorporated in 2005 and is based in Aliso Viejo, California. As of October 16, 2015, AqueSys, Inc. operates as a subsidiary of Allergan plc.

Cydan

Venture Round in 2017
Cydan II, Inc. is a drug accelerator which develops therapies for rare genetic diseases. The company evaluates products for treating rare genetic diseases and further development by biotechnology companies. The company conducts de-risking studies on diseases and disorders with a genetic etiology. It develops therapies for Niemann-Pick Disease Type C and IMR-687, a treatment for sickle cell disease. The company was founded in 2013 and is based in Cambridge, Massachusetts.

amunix

Series A in 2020
Amunix Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops protein and peptide therapeutics products for cancer. It focuses on XTEN, a half-life extension platform; XPAT (XTENylated Protease-Activated T Cell Engager) platform using its XTEN technology to analyze protease activity in the tumor microenvironment; and Protease Triggered Immune Activator (ProTIA), an immuno-oncology therapeutic. The company caters to the academic, biotechnology, and pharmaceutical sectors. It has strategic partnerships with Janssen, Biogen-Idec, Noxxon, Baxalta, Ambrx, Seattle Genetics, and Versartis. The company was formerly known as Amunix, Inc. Amunix Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Mountain View, California.

Collegium Pharmaceutical

Venture Round in 2015
Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of proprietary, late-stage pharmaceutical products. These products address the growing problems associated with non-medical use and abuse of prescription drugs through formulation based improvements protected by intellectual property (IP). Collegium is focused on building a portfolio of products for the treatment of chronic pain that possess tamper-resistant features and provide extended-release delivery using its patent-protected DETERx formulation platform.

Rapid Micro Biosystems

Series C in 2015
Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to Rapid Micro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.

RxSight

Venture Round in 2015
RxSight is a medical device company that offers an intraocular lens and cataract surgery solutions. Using a proprietary light treatment that produces precise modifications in lens curvature, RxSight’s Light Adjustable Lens (RxLAL) enables doctors and patients to predictably optimize vision after cataract surgery through an office-based IOL enhancement. The company’s mission is to revolutionize the premium cataract surgery experience by allowing surgeons to partner with their patients to achieve optimized results for every unique eye. It was founded in 1997 and is headquartered in Aliso Viejo, California, United States.

Axonics Modulation Technologies

Series C in 2018
Axonics is a pre-revenue company developing novel implantable neuromodulation technology licensed from The Alfred Mann Foundation directed toward a number of clinical indications, including the treatment of chronic pain and overactive bladder.

Epirium

Private Placement in 2019
Epirium Bio, Inc. develops compounds for treatment of cardiovascular diseases and metabolic syndrome. Epirium Bio, Inc. was formerly known as Cardero Therapeutics, Inc. The company was incorporated in 2008 and is based in San Diego, California.

CardioDx

Private Equity Round in 2011
CardioDx, Inc., a molecular diagnostics company, develops tests for coronary artery disease (CAD), cardiac arrhythmia, and heart failure. It develops Corus CAD, a blood test that helps primary care clinicians and cardiologists to assess whether or not non-diabetic patient’s chest discomfort or other symptoms are due to obstructive CAD. The company serves customers in the United States. CardioDx, Inc. was incorporated in 2003 and is based in Redwood City, California.

Epirium Bio

Series A in 2019
Cardero Therapeutics is a start-up pharmaceutical company that is developing a novel class of therapeutics that induces the formation of new mitochondria (mitochondrial biogenesis) and enhances mitochondrial function in response to metabolic demand. Chronic depletion of mitochondria, the principal source of cellular ATP, has been directly linked to the progression of heart failure, sarcopenia, and neurodegeneration. Cardero Therapeutics is collaborating with numerous academic medical centers to advance novel drug candidates structurally based on a newly discovered human hormone that appears to fundamentally regulate mitochondrial density and function in all tissues. Cardero Therapeutics believes that enhancing myocyte bioenergetics will comprise an innovative therapeutic approach complementary to currently available cardiovascular drugs. The company’s clinical development focus is the lethal cardiomyopathy associated with orphan diseases characterized by loss of mitochondria in muscle and heart, resulting in heart failure that is poorly responsive to current medical interventions. Initial clinical trials are directed toward Duchenne muscular dystrophy and Friedreich’s ataxia.

Axonics Modulation Technologies, Inc. (NasdaqGS:AXNX)

Private Placement in 2017
Axonics Modulation Technologies, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems in the United States and internationally. The company’s SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence, and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company was formerly known as American Restorative Medicine, Inc. and changed its name to Axonics Modulation Technologies, Inc. in August 2013. Axonics Modulation Technologies, Inc. was incorporated in 2012 and is based in Irvine, California.

Corcept Therapeutics

Post in 2009
Since our founding in May 1998 we have been focused on the impact of cortisol and the potential benefits of developing glucocorticoid receptor antagonists. About 80 percent of the tissues in the body have receptors for cortisol, and the effects of excess cortisol are severe and often life-threatening. Our initial research has been with mifepristone, which potently blocks the cortisol receptor. On February 17, 2012, the FDA approved Korlym® (mifepristone) in the United States as a once-daily oral medication for treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. Mifepristone is also being studied in a phase 3 trial, evaluating the impact of cortisol blockade on the psychotic features of psychotic depression. We plan to continue enrolling patients in this study throughout 2013.

CardioDx

Private Equity Round in 2012
CardioDx, Inc., a molecular diagnostics company, develops tests for coronary artery disease (CAD), cardiac arrhythmia, and heart failure. It develops Corus CAD, a blood test that helps primary care clinicians and cardiologists to assess whether or not non-diabetic patient’s chest discomfort or other symptoms are due to obstructive CAD. The company serves customers in the United States. CardioDx, Inc. was incorporated in 2003 and is based in Redwood City, California.

Civitas Therapeutics

Series A in 2011
Civitas Therapeutics is a biopharmaceutical company that focuses on developing pulmonary delivery therapies. The Company develops therapeutics for the treatment of central nervous system and respiratory disorders. It serves patients throughout the United States.

Talaris Therapeutics

Series B in 2020
Talaris Therapeutics is a operator of a biotechnology company engaged in the development of innovative cellular therapies. The company's proprietary allogeneic cell therapy product has shown to induce tolerance in recipients of solid organ transplants from unmatched and unrelated donors, enabling living donor kidney transplant recipients to wean completely off immunosuppression one year after transplant.

Velomedix

Series A in 2009
Velomedix, Inc. is a therapeutic hypothermia company in the United States. Its therapeutic hypothermia technology offers a novel solution for the protection of the body's organs during ischemic or inflammatory insults. Velomedix, Inc. is based in Menlo Park, California.

Solta Medical

Post in 2010
Solta Medical - Medical Aesthetic Devices > Splash

AvengeBio

Seed Round in 2020
AvengeBio is focusing on Cell-Generated Immunotherapies to eradicate solid tumors. It is a developer of a drug delivery platform intended to treat cancer. The company was founded in 2019 and based in Cambridge, Massachusetts.

Vaxcyte

Series A in 2015
Vaxcyte, formerly known as SutroVax, is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, comprising the XpressCFTM platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte’s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. In addition to its pneumococcal conjugate vaccines in development, VAX-24 and VAX-XP, Vaxcyte is leveraging its proprietary platform to advance other novel vaccines, including a prophylactic vaccine to prevent Group A Strep infections (VAX-A1) and a therapeutic vaccine to treat periodontal disease (VAX-PG).

Nalu Medical

Venture Round in 2022
Nalu Medical is an early-stage company that develops a range of medical devices. Their vision to modernize and improve the technology in medical devices, thus improving the lives of people. The Nalu neurostimulation system is a battery-free, micro-implantable pulse generator (iPG) currently cleared by the FDA for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) for mitigating chronic pain. The company was founded in 2014 and is based in Carlsbad, California.

Vaxcyte, Inc. (NasdaqGS:PCVX)

Private Placement in 2017
Vaxcyte, Inc., a preclinical-stage biotechnology vaccine company, develops vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains causing significant invasive pneumococcal disease and antibiotic resistance; VAX-A1, a conjugate vaccine candidate for protection against subtypes of Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was founded in 2013 and is headquartered in Foster City, California.

Rapid Micro Biosystems

Series B in 2013
Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to Rapid Micro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.

Velicept Therapeutics

Private Placement in 2015
Velicept Therapeutics, Inc., a clinical development company, develops and commercializes drugs that have the potential to improve patients’ lives by transforming the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS). Its lead program include Solabegron, a differentiated and selective compound that relaxes the bladder smooth muscle by stimulating beta 3-adrenoceptors, which is being investigated for OAB and IBS conditions that affect the quality of life. The company was founded in 2015 and is based in Malvern, Pennsylvania.

Endeavor BioMedicines

Series B in 2022
Endeavor BioMedicines is developing new treatments targeting the underlying causes of pulmonary fibrosis.

KaNDy Therapeutics

Private Placement in 2018
KANDY THERAPEUTICS LIMITED develops non-hormonal treatment for multiple symptoms of the menopause including hot flashes and night time awakening. The company offers NT-814, a drug for common, chronic debilitating female sex-hormone related treatment. It provides non-hormonal therapy to treat moderate to severe post-menopausal vasomotor symptoms, enabling patients to receive treatment, and reduce symptoms of hormone related conditions. The company was founded in 2017 and is based in Stevenage, United Kingdom. KANDY THERAPEUTICS LIMITED operates as a subsidiary of Bayer Aktiengesellschaft.

Poseida Therapeutics

Private Placement in 2019
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing a pipeline of solutions for the treatment of hematological malignancies and solid tumors, as well as vivo programs for liver-directed gene therapies for rare diseases. In addition, it offers CAR-T therapies for the treatment for cancer. Further, it offers gene therapies for rare and life-threatening diseases, including Ornithine transcarbamylase (OTC) deficiency and methylmalonic acidemia (MMA), and genetic liver diseases. The company was founded in 2014 and is headquartered in San Diego, California.

Helomics

Venture Round in 2008
Helomics® is a comprehensive personalized healthcare company, bringing the next generation of diagnostics to the oncology field. Helomics is dedicated to improving patient outcomes by providing a personalized comprehensive tumor profile utilizing a proprietary set of laboratory platforms that leverage both tissue-based live and fixed cellular based analysis allowing physicians to characterize malignant tumors on a personalized basis. Helomics’ novel molecular and cellular markers and bioinformatics services support treatment decisions by providing vital information based on the specific biological processes of each individual’s cancer.

Vera Therapeutics

Series C in 2021
Trucode Gene Repair, Inc. operates a triplex gene editing platform for curing genetic diseases. It focuses on sickle cell disease and cystic fibrosis. The company develops a pipeline of novel, proprietary therapeutic products for high-penetrance disease genes to alleviate and cure genetic disorders in patients. The company was founded in 2016 and is based in South San Francisco, California.

Poseida Therapeutics

Series C in 2019
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing a pipeline of solutions for the treatment of hematological malignancies and solid tumors, as well as vivo programs for liver-directed gene therapies for rare diseases. In addition, it offers CAR-T therapies for the treatment for cancer. Further, it offers gene therapies for rare and life-threatening diseases, including Ornithine transcarbamylase (OTC) deficiency and methylmalonic acidemia (MMA), and genetic liver diseases. The company was founded in 2014 and is headquartered in San Diego, California.

Tricida

Series C in 2016
Tricida, Inc. is a late-stage pharmaceutical company focused on the development and commercialization of its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. Metabolic acidosis has been associated with increased muscle wasting, loss of bone density and death.

Zavante Therapeutics

Series A in 2016
Zavante Therapeutics, Inc., a biopharmaceutical company, engages in developing medicines for the treatment of diseases that affect patients in the hospital setting. Its products in pipeline include ZOLYD, an investigational injectable antibiotic under development to combat serious and life-threatening infections, including those due to multi-drug resistant gram-negative and gram-positive bacteria. The company was incorporated in 2013 and is based in San Diego, California. As of July 24, 2018, Zavante Therapeutics, Inc. operates as a subsidiary of Nabriva Therapeutics plc.

Somatus

Series C in 2020
Somatus is a healthcare company that partners with health plans, health systems, and nephrology, and primary care groups. It provides integrated care for patients with or at risk of developing kidney disease. Somatus' is vertically integrated clinical services and technology delay or prevent disease progression, improve quality and care coordination, and increase the use of home dialysis modalities and rates of kidney transplantation. The company is headquartered in McLean, Virginia, and founded by a team of world-class healthcare operators, successful entrepreneurs, and leading clinicians treating kidney disease.

Venus Concept

Venture Round in 2014
Venus Concept is a progressive thinking company driven by their passion to create cutting edge technologies and products. While resting on strong ethical morals, they push boundaries in order to create new standards in the medical aesthetics industry. Led by a team of experienced executives and researchers, world renowned for their achievements in the medical aesthetics industry, Venus Concept is delivering the promise of a more effective, more pleasant and more profitable experience.

Encore Dermatology

Debt Financing in 2019
Encore Dermatology is a privately held fully-integrated dermatology company that provides prescription therapies and medical devices to dermatologists. It provides a range of medical dermatology products, treating a number of topical disease states that enable patients to get improved skin care and treatment with ease. Encore Dermatology was established in 2015 and is headquartered in Malvern, Pennsylvania.

KaNDy Therapeutics

Series C in 2018
KANDY THERAPEUTICS LIMITED develops non-hormonal treatment for multiple symptoms of the menopause including hot flashes and night time awakening. The company offers NT-814, a drug for common, chronic debilitating female sex-hormone related treatment. It provides non-hormonal therapy to treat moderate to severe post-menopausal vasomotor symptoms, enabling patients to receive treatment, and reduce symptoms of hormone related conditions. The company was founded in 2017 and is based in Stevenage, United Kingdom. KANDY THERAPEUTICS LIMITED operates as a subsidiary of Bayer Aktiengesellschaft.

Checkmate Pharmaceuticals

Series C in 2020
Checkmate Pharmaceuticals, Inc., a biotechnology company, develops novel immunotherapies for the treatment of cancer. It engages in the field of CpG oligonucleotides and validates an approach that combines the ability of CpG DNA to activate an anti-tumor T-cell response with checkpoint inhibition to overcome a tumor’s ability to mute the immune response. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

Crownwheel Partners

Seed Round in 2013
Crownwheel Partners provides liquidity and financing solutions to royalty owners and companies in the global healthcare sector. Founded in 2013, CrownWheel invests in commercial and late-stage products through the full or partial monetization of royalty streams, revenue participation, the purchase of structured debt and equity, and the acquisition of legacy or non-core products.

Rapid Micro Biosystems

Private Placement in 2020
Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to Rapid Micro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.

Eargo

Private Placement in 2020
Eargo, Inc., a consumer-focused medical device company, develops and sells hearing aids to assist people with hearing loss in the United States. It sells its products through online stores. The company was formerly known as Aria Innovations, Inc. and changed its name to Eargo, Inc. in November 2014. Eargo, Inc. was founded in 2010 and is headquartered in San Jose, California.

LEXEO Therapeutics

Series B in 2021
LEXEO Therapeutics is a fully integrated biotechnology company. LEXEO Therapeutics’ pipeline consists of adeno-associated virus (AAV)-mediated therapies primarily developed at Weill Cornell Medicine’s Department of Genetic Medicine. Beyond LEXEO Therapeutics’ lead programs – which are focused on both rare and non-rare monogenic (single genemutation) diseases – the company’s preclinical pipeline spans monogenic diseases, as well as hereditary and acquired diseases across a spectrum of patient population sizes and a range of unmet medical needs. Importantly, LEXEO Therapeutics will focus on advancing clinical programs through to commercialization, with the goal of maintaining an ongoing research collaboration with Weill Cornell Medicine’s Department of Genetic Medicine to help advance the company’s pre-clinical pipeline.

Quanta Therapeutics

Series C in 2021
Quanta is a biotechnology company uncovering novel cancer therapeutic candidates using allosteric modulation to target driver oncogenes. The company was founded in 2018 and is based in San Francisco, CA.

AqueSys

Series C in 2010
AqueSys, Inc., an ophthalmic company, focuses on innovating and commercializing implantable devices that improves the treatment of glaucoma. It offers XEN, a gel stent that creates a diffuse outflow of aqueous from the anterior chamber into the non-dissected tissue of the subconjunctival space. The company’s XEN gel stent creates a new pathway to allow the excess fluid in eyes to flow out, and lowers the eye pressure. AqueSys, Inc. was incorporated in 2005 and is based in Aliso Viejo, California. As of October 16, 2015, AqueSys, Inc. operates as a subsidiary of Allergan plc.

Talaris Therapeutics

Private Placement in 2020
Talaris Therapeutics is a operator of a biotechnology company engaged in the development of innovative cellular therapies. The company's proprietary allogeneic cell therapy product has shown to induce tolerance in recipients of solid organ transplants from unmatched and unrelated donors, enabling living donor kidney transplant recipients to wean completely off immunosuppression one year after transplant.

Neurana Pharmaceuticals

Series A in 2018
Neurana Pharmaceuticals, Inc. is a pharmaceutical company that develops treatment for neuromuscular conditions, including acute and painful muscle spasms of the neck and back. The company provides Tolperisone, a therapeutic compound that treats musculoskeletal conditions, including neuromuscular spasms and spasticity without sedation. The company was formerly known as Katama Pharmaceuticals Inc. Neurana Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in San Diego, California.

Rivus Pharmaceuticals

Series A in 2021
Rivus Pharmaceuticals operates as a biopharmaceutical company dedicated to improving cardio-metabolic health. Rivus Pharmaceuticals is dedicated to improving cardio-metabolic health by developing controlled metabolic accelerators (CMAs) that address the underlying metabolic risk factors for cardiovascular mortality and morbidity.

PixelOptics

Series C in 2008
PixelOptics was founded in 2005 as the world's first composite lens company. Their unique and proprietary approach to lens design combines sound lens design principles and well-known, proven lens materials to create entirely new categories of eyeglass lenses.

InfaCare Pharmaceutical

Series B in 2008
InfaCare Pharmaceutical, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceuticals for the neonatal and pediatric patient population. Its neonatal product, Stanate, is under development for the pharmacologic treatment of infantile jaundice or hyperbilirubinemia. The company was founded in 2005 and is based in Trevose, Pennsylvania.

Aptinyx

Series B in 2017
Aptinyx Inc. is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovering proprietary compounds that work through a novel mechanism: modulation of the NMDA receptor to enhance pathways involved with nerve cell communication. This mechanism has applicability across a number of CNS disorders. Our goal is to rapidly advance our most promising drug candidates into clinical development for indications with high unmet medical need.

BAROnova

Series D in 2015
BAROnova, Inc., a clinical-stage medical-device company, engages in developing non-surgical non-pharmacologic devices to induce weight loss. It develops TransPyloric Shuttle, a device that is inserted into the stomach through the mouth using a simple endoscopic procedure, as well as causes a patient’s stomach to fill up faster, stay full longer, and delay gastric emptying. BAROnova, Inc. was formerly known as Polymorfix, Inc. BAROnova, Inc. was founded in 2006 and is based in San Jose, California.

Esperion

Venture Round in 2013
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.

Collegium Pharmaceutical

Venture Round in 2012
Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of proprietary, late-stage pharmaceutical products. These products address the growing problems associated with non-medical use and abuse of prescription drugs through formulation based improvements protected by intellectual property (IP). Collegium is focused on building a portfolio of products for the treatment of chronic pain that possess tamper-resistant features and provide extended-release delivery using its patent-protected DETERx formulation platform.

Epirium

Series A in 2019
Epirium Bio, Inc. develops compounds for treatment of cardiovascular diseases and metabolic syndrome. Epirium Bio, Inc. was formerly known as Cardero Therapeutics, Inc. The company was incorporated in 2008 and is based in San Diego, California.

Amphora Medical

Series B in 2017
Amphora Medical is a Minnesota-based developer of medical devices and instruments. The company is currently working on a novel cystoscopic device that has the potential to improve bladder function and quality of life for people with Overactive Bladder Syndrome (OAB). It was founded in 2011 and is headquartered in Minneapolis, Minnesota, United States.

Rapid Micro Biosystems

Venture Round in 2020
Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to Rapid Micro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.

PreCision Dermatology

Debt Financing in 2013
PreCision Dermatology is a fully-integrated dermatology company with a mission to deliver innovative therapies to doctors and patients that demonstrably improve the care of skin. PreCision Dermatology is expanding rapidly through internally generated innovation, acquisitions, in-licensing, and co-marketing opportunities.

Somatus

Series E in 2022
Somatus is a healthcare company that partners with health plans, health systems, and nephrology, and primary care groups. It provides integrated care for patients with or at risk of developing kidney disease. Somatus' is vertically integrated clinical services and technology delay or prevent disease progression, improve quality and care coordination, and increase the use of home dialysis modalities and rates of kidney transplantation. The company is headquartered in McLean, Virginia, and founded by a team of world-class healthcare operators, successful entrepreneurs, and leading clinicians treating kidney disease.

WelbeHealth

Series B in 2018
At WelbeHealth, we envision a world in which every human being is able to participate fully in life through their final days. We serve frail seniors through a model of comprehensive medical and social care called PACE (Program of All-Inclusive Care for the Elderly), helping our participants live better, longer, and more independently. Founded by a seasoned group of physician entrepreneurs, our leadership team hails from leading payer and provider organizations such as GoHealth Urgent Care, BAYADA Home Health, AirStrip Technologies, Evolent Health, and On Lok. With funding from leading venture capital firms, we're looking for team members who are inspired to help us deliver on our mission of unlocking the full potential of the most vulnerable seniors in our communities. Our colleagues are energized by working in diverse groups toward our shared purpose, are eager to drive groundbreaking innovations, and have the courage to care for our participants with empathy and love.

Sublimity Therapeutics

Private Placement in 2018
Sublimity Therapeutics (formerly Sigmoid Pharma), is a specialty pharma company with offices in Dublin, Ireland, and Solana Beach, California. Sublimity’s goal is to identify and create meaningful new therapies for unmet clinical needs in gastrointestinal and immunological diseases. Sublimity’s priority focus is on its lead product, STI-0529, for treatment of moderate to severe ulcerative colitis.

Theseus Pharmaceuticals

Series B in 2021
Theseus Pharmaceuticals is a Technology based company.

Inozyme

Private Placement in 2018
Inozyme is a provider of therapies for rare diseases of calcification affecting soft tissues and bone created to offer potentially disease-modifying therapies to help children who are affected with rare, but severe and debilitating disorders of metabolism. The company's enzyme replacement therapy provides the treatment of Generalized Arterial Calcification of Infancy (GACI) and Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2), enabling patients to treat diseases characterized by mineral imbalances in the body.

Velicept Therapeutics

Series B in 2018
Velicept Therapeutics, Inc., a clinical development company, develops and commercializes drugs that have the potential to improve patients’ lives by transforming the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS). Its lead program include Solabegron, a differentiated and selective compound that relaxes the bladder smooth muscle by stimulating beta 3-adrenoceptors, which is being investigated for OAB and IBS conditions that affect the quality of life. The company was founded in 2015 and is based in Malvern, Pennsylvania.

Aptus Endosystems

Series B in 2012
Aptus Endosystems, Inc., a medical device company, develops, manufactures, and distributes endograft anchoring systems for endovascular aneurysm repair (EVAR). The company offers Heli-FX EndoAnchor system for the treatment of abdominal and thoracic aortic aneurysmal disease; and Heli-FX thoracic endoanchor system, a longer delivery device to enhance the long term durability of thoracic EVAR. It also provides Aptus TourGuide, a steerable sheath that enables quick access and delivery of peripheral vascular products. The company serves customers in the United States, Germany, Italy, the Netherlands, and the United Kingdom. It offers its products through distributors. The company was incorporated in 2002 and is based in Sunnyvale, California. As of June 19, 2015, Aptus Endosystems, Inc. operates as a subsidiary of Medtronic plc.

LEXEO Therapeutics

Series A in 2021
LEXEO Therapeutics is a fully integrated biotechnology company. LEXEO Therapeutics’ pipeline consists of adeno-associated virus (AAV)-mediated therapies primarily developed at Weill Cornell Medicine’s Department of Genetic Medicine. Beyond LEXEO Therapeutics’ lead programs – which are focused on both rare and non-rare monogenic (single genemutation) diseases – the company’s preclinical pipeline spans monogenic diseases, as well as hereditary and acquired diseases across a spectrum of patient population sizes and a range of unmet medical needs. Importantly, LEXEO Therapeutics will focus on advancing clinical programs through to commercialization, with the goal of maintaining an ongoing research collaboration with Weill Cornell Medicine’s Department of Genetic Medicine to help advance the company’s pre-clinical pipeline.

RxSight

Debt Financing in 2015
RxSight is a medical device company that offers an intraocular lens and cataract surgery solutions. Using a proprietary light treatment that produces precise modifications in lens curvature, RxSight’s Light Adjustable Lens (RxLAL) enables doctors and patients to predictably optimize vision after cataract surgery through an office-based IOL enhancement. The company’s mission is to revolutionize the premium cataract surgery experience by allowing surgeons to partner with their patients to achieve optimized results for every unique eye. It was founded in 1997 and is headquartered in Aliso Viejo, California, United States.

Tiburio Therapeutics

Series A in 2019
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.The company's compounds aid in the treatment of non-functioning pituitary adenoma using a dopamine-somatostatin chimeric molecule that has the potential to shrink or halt tumor growth, providing patients with effective treatment for rare neuroendocrine tumors and endocrine diseases.

Civitas Therapeutics

Series C in 2014
Civitas Therapeutics is a biopharmaceutical company that focuses on developing pulmonary delivery therapies. The Company develops therapeutics for the treatment of central nervous system and respiratory disorders. It serves patients throughout the United States.

CuraSen Therapeutics

Series A in 2018
Curasen Therapeutics Inc. operates as a biotechnology company which develops therapies to treat neurodegenerative diseases. It also develops small molecule drugs that targets a novel mechanism in the brain to restore function, improve symptoms, and modify diseases, such as less common (orphan) neurodegenerative disorders, and Parkinson's disease and Alzheimer's disease. The company was incorporated in 2016 and is based in Los Altos, California.

Endeavor BioMedicines

Series A in 2021
Endeavor BioMedicines is developing new treatments targeting the underlying causes of pulmonary fibrosis.

Sydnexis

Series B in 2021
Sydnexis is engaged in the development of a proprietary treatment for pediatric progressive myopia, a major global unmet medical need. Sydnexis manufactures pharmaceutical product for ophthalmic disorder or condition.

Poseida Therapeutics

Private Placement in 2018
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing a pipeline of solutions for the treatment of hematological malignancies and solid tumors, as well as vivo programs for liver-directed gene therapies for rare diseases. In addition, it offers CAR-T therapies for the treatment for cancer. Further, it offers gene therapies for rare and life-threatening diseases, including Ornithine transcarbamylase (OTC) deficiency and methylmalonic acidemia (MMA), and genetic liver diseases. The company was founded in 2014 and is headquartered in San Diego, California.

Murj, Inc.

Private Placement in 2018
Murj, Inc. operates in the technology industry. The company was incorporated in 2014 and is based in Santa Cruz, California.

CardioDx

Private Equity Round in 2012
CardioDx, Inc., a molecular diagnostics company, develops tests for coronary artery disease (CAD), cardiac arrhythmia, and heart failure. It develops Corus CAD, a blood test that helps primary care clinicians and cardiologists to assess whether or not non-diabetic patient’s chest discomfort or other symptoms are due to obstructive CAD. The company serves customers in the United States. CardioDx, Inc. was incorporated in 2003 and is based in Redwood City, California.

Eargo

Series E in 2020
Eargo, Inc., a consumer-focused medical device company, develops and sells hearing aids to assist people with hearing loss in the United States. It sells its products through online stores. The company was formerly known as Aria Innovations, Inc. and changed its name to Eargo, Inc. in November 2014. Eargo, Inc. was founded in 2010 and is headquartered in San Jose, California.

Velicept Therapeutics

Series B in 2015
Velicept Therapeutics, Inc., a clinical development company, develops and commercializes drugs that have the potential to improve patients’ lives by transforming the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS). Its lead program include Solabegron, a differentiated and selective compound that relaxes the bladder smooth muscle by stimulating beta 3-adrenoceptors, which is being investigated for OAB and IBS conditions that affect the quality of life. The company was founded in 2015 and is based in Malvern, Pennsylvania.

Molecular Templates

Post in 2017
Molecular Templates Inc. (MTI) is a biopharmaceutical company with a novel protein platform for the development of new therapeutics against cancer. The company has a lead compound for melanoma that is expected to enter into clinical trials in the next two years and is developing additional compounds against a variety of other cancers.

Venus Concept

Merger/Acquisition in 2015
Venus Concept is a progressive thinking company driven by their passion to create cutting edge technologies and products. While resting on strong ethical morals, they push boundaries in order to create new standards in the medical aesthetics industry. Led by a team of experienced executives and researchers, world renowned for their achievements in the medical aesthetics industry, Venus Concept is delivering the promise of a more effective, more pleasant and more profitable experience.

Solta Medical

Post in 2010
Solta Medical - Medical Aesthetic Devices > Splash

Vaxcyte

Series B in 2017
Vaxcyte, formerly known as SutroVax, is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, comprising the XpressCFTM platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte’s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. In addition to its pneumococcal conjugate vaccines in development, VAX-24 and VAX-XP, Vaxcyte is leveraging its proprietary platform to advance other novel vaccines, including a prophylactic vaccine to prevent Group A Strep infections (VAX-A1) and a therapeutic vaccine to treat periodontal disease (VAX-PG).

CuraSen Therapeutics

Private Placement in 2018
Curasen Therapeutics Inc. operates as a biotechnology company which develops therapies to treat neurodegenerative diseases. It also develops small molecule drugs that targets a novel mechanism in the brain to restore function, improve symptoms, and modify diseases, such as less common (orphan) neurodegenerative disorders, and Parkinson's disease and Alzheimer's disease. The company was incorporated in 2016 and is based in Los Altos, California.

Alphaeon

Series A in 2015
ALPHAEON Corporation develops beauty, wellness, and lifestyle products for customers in the United States and internationally. It offers nutritional supplements that include Omega-3 supplements for skin wellness; beauty products for improving the appearance of fine lines and wrinkles, dull and dry skin, and thinning eyelashes; and PRN Omega-3 products for eye health. The company also provides plastic surgery, ophthalmology, and dermatology financing services. It offers its products online. ALPHAEON Corporation was incorporated in 2012 and is based in Irvine, California.

Vaxcyte, Inc. (NasdaqGS:PCVX)

Private Placement in 2018
Vaxcyte, Inc., a preclinical-stage biotechnology vaccine company, develops vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains causing significant invasive pneumococcal disease and antibiotic resistance; VAX-A1, a conjugate vaccine candidate for protection against subtypes of Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was founded in 2013 and is headquartered in Foster City, California.

Sympara Medical

Seed Round in 2013
Sympara Medical is a medical company that focuses on developing novel therapies for hypertension. It was established in 2012 and is based in San Francisco, California.

AvengeBio

Series A in 2022
AvengeBio is focusing on Cell-Generated Immunotherapies to eradicate solid tumors. It is a developer of a drug delivery platform intended to treat cancer. The company was founded in 2019 and based in Cambridge, Massachusetts.

Neurana Pharmaceuticals

Private Placement in 2018
Neurana Pharmaceuticals, Inc. is a pharmaceutical company that develops treatment for neuromuscular conditions, including acute and painful muscle spasms of the neck and back. The company provides Tolperisone, a therapeutic compound that treats musculoskeletal conditions, including neuromuscular spasms and spasticity without sedation. The company was formerly known as Katama Pharmaceuticals Inc. Neurana Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in San Diego, California.

Inozyme

Series A in 2019
Inozyme is a provider of therapies for rare diseases of calcification affecting soft tissues and bone created to offer potentially disease-modifying therapies to help children who are affected with rare, but severe and debilitating disorders of metabolism. The company's enzyme replacement therapy provides the treatment of Generalized Arterial Calcification of Infancy (GACI) and Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2), enabling patients to treat diseases characterized by mineral imbalances in the body.

CardioDx

Venture Round in 2017
CardioDx, Inc., a molecular diagnostics company, develops tests for coronary artery disease (CAD), cardiac arrhythmia, and heart failure. It develops Corus CAD, a blood test that helps primary care clinicians and cardiologists to assess whether or not non-diabetic patient’s chest discomfort or other symptoms are due to obstructive CAD. The company serves customers in the United States. CardioDx, Inc. was incorporated in 2003 and is based in Redwood City, California.

Alphaeon

Series B in 2015
ALPHAEON Corporation develops beauty, wellness, and lifestyle products for customers in the United States and internationally. It offers nutritional supplements that include Omega-3 supplements for skin wellness; beauty products for improving the appearance of fine lines and wrinkles, dull and dry skin, and thinning eyelashes; and PRN Omega-3 products for eye health. The company also provides plastic surgery, ophthalmology, and dermatology financing services. It offers its products online. ALPHAEON Corporation was incorporated in 2012 and is based in Irvine, California.

Cortica

Series C in 2021
Cortica Inc. provides neurological therapies for children with autism and other neurodevelopmental challenges. It offers customized treatment programs for children with autism based on an in-depth understanding of the child's neurobiology and developmental profile. The company provides in-home, in-clinic, and telehealth services. Cortica Inc. was incorporated in 2014 and is based in San Diego, California. It has centers in Carlsbad, Irvine, San Rafael, Torrance, and Westlake Village, California.

Civitas Therapeutics

Series B in 2013
Civitas Therapeutics is a biopharmaceutical company that focuses on developing pulmonary delivery therapies. The Company develops therapeutics for the treatment of central nervous system and respiratory disorders. It serves patients throughout the United States.

Rapid Micro Biosystems

Private Placement in 2018
Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to Rapid Micro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.

Aptinyx

Series A in 2016
Aptinyx Inc. is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovering proprietary compounds that work through a novel mechanism: modulation of the NMDA receptor to enhance pathways involved with nerve cell communication. This mechanism has applicability across a number of CNS disorders. Our goal is to rapidly advance our most promising drug candidates into clinical development for indications with high unmet medical need.

Aimmune Therapeutics

Series B in 2015
Aimmune Therapeutics is a company operating in the United States biotechnology industry. Its main focus is in the development of product candidates to combat peanut and other food allergies. The company's therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy, is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols, and support services.

LimFlow SA

Series D in 2022
LimFlow System is approved for sale in markets regulated by the CE Mark. Investigational device in the United States. Limited by U.S. federal law to investigational use only in the U.S. LimFlow is a game-changing technology that enables clinicians to bring new hope to end-stage chronic limb ischemia (CLI) patients, when all other revascularization efforts have been exhausted. By restoring perfusion to the ischemic foot through a completely novel, percutaneous procedure, the LimFlow System can relieve ischemic pain, promote wound healing, reduce amputations and restore mobility for patients when used as part of a multi-disciplinary team approach.

amunix

Private Placement in 2020
Amunix Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops protein and peptide therapeutics products for cancer. It focuses on XTEN, a half-life extension platform; XPAT (XTENylated Protease-Activated T Cell Engager) platform using its XTEN technology to analyze protease activity in the tumor microenvironment; and Protease Triggered Immune Activator (ProTIA), an immuno-oncology therapeutic. The company caters to the academic, biotechnology, and pharmaceutical sectors. It has strategic partnerships with Janssen, Biogen-Idec, Noxxon, Baxalta, Ambrx, Seattle Genetics, and Versartis. The company was formerly known as Amunix, Inc. Amunix Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Mountain View, California.